Nevertheless, several previous reports have indicated that these pro-apoptotic mediators triggered by Aβs, including PKCδ, CDK5, and STAT3, may serve as potential biomarkers in plasma or cerebrospinal fluid (CSF) for AD in clinical settings. This evidence concerns the gene STAT3 and Alzheimer disease.